To study the effect of using recombinant human growth hormone (rhGH) in growth retarded children with chronic kidney disease (CKD).
This was a non-randomized controlled study over 2 years including children in CKD stages 4-5 suffering from growth retardation. Children were divided into rhGH-treated or non-rhGH treated groups.
A total of 70 children (35 in each group) were enrolled. While the mean (SD) height of 35 children with CKD had increased from 109.5 (26) cm to 116 (26) cm (mean growth velocity 6.5 cm/year; P=0.09) prior to rhGH therapy, the same was found to increase from 116 (26) cm at the start of therapy to 125 (25) cm after one year of therapy (P=0.02).
Therapy with rhGH was helpful in catch-up growth in Tunisian children with CKD.
Therapy with rhGH was helpful in catch-up growth in Tunisian children with CKD.To explore association between serum ferritin and severity of sepsis among children, and relate levels to the final outcome.
This observational study was conducted in a tertiary care hospital between I February and 30 July, 2019. Serum ferritin level was estimated in children (age 6 months to 12 years) suffering from sepsis, irrespective of the probable etiology. Children with hemoglobinopathies, autoimmune diseases, previous blood transfusion, severe acute malnutrition, hemophagocytic lymphohistiocytosis and chronic hepatitis were excluded. The ferritin level was measured sequentially at pre-defined stages of illness viz., sepsis, severe sepsis, septic shock and multiorgan dysfunction syndrome (MODS). Association between serum ferritin and severity of sepsis was analyzed, and ferritin level was related to the final outcome of death or recovery by receiver operating characteristic (ROC) curve analysis.
The study group included 47 children with sepsis who progressed to a state of MODS; 32 recovered from MODS. Significant differences in serum ferritin level were observed with severity of sepsis. There was clear demarcation of ferritin levels between sepsis severity stages. The proportion of death among the 47 MODS cases was 31.9% (95% CI 18.6 - 45.2%). ROC analysis in the MODS group indicated that serum ferritin &gt;1994.3 ng/mL predicts mortality (AUC 0.73 [95% CI 0.58-0.85]) with sensitivity 66.7% [95% CI 38.4-88%] and specificity 100.0% [95% CI 89.1-100%].
There is clear demarcation of serum ferritin levels that can help differentiation of sepsis severity stages in children with sepsis. There is no such demarcation between survivors and non-survivors in MODS cases.
There is clear demarcation of serum ferritin levels that can help differentiation of sepsis severity stages in children with sepsis. There is no such demarcation between survivors and non-survivors in MODS cases.To compare effectiveness, safety and tolerance of two colon cleansing regimens using polyethylene glycol 4000 (PEG) in children.
Prospective, randomized, open clinical trial carried out in 129 children, 3 to 18 years old undergoing colonoscopy. Patients were randomized into two groups, 64 children received PEG with electrolyte (50 mL/kg) and oral bisacodyl (PEG+B) group or 65 other children received PEG with electrolyte (70 mL/kg) and glycerol enema (PEG+G) group.
Both regimens showed a good colon cleansing effectiveness with the percentage of successful cleansing being 93.8% for PEG+B regimen and 89.1% for PEG+G regimen (P=0.510). There was no statistically significant difference between the pre-regimen and post-regimen laboratory values. https://www.selleckchem.com/products/pi3k-hdac-inhibitor-i.html The rates of nausea (65.6% vs 31.3%; P&lt;0.001) and bloating (50% vs 17.2%; P&lt;0.001) of PEG+G group were significantly higher than that of PEG+B group.
Both regimens had good efficacy and safety for clon cleansing in children. The tolerance of PEG+B regimen was better.
Both regimens had good efficacy and safety for clon cleansing in children. The tolerance of PEG+B regimen was better.Institutional physiotherapy as a standard of care for management of cerebral palsy (CP) has certain shortcomings, especially in resource-constrained settings. This is a proof-of-concept trial to evaluate the efficacy of individualized home-centered activity-based therapy in children with spastic diplegic CP.
Randomized controlled trial (open-label).
Tertiary-care hospital with pediatric neurology services (July 2014 to July 2016).
Consecutive sample of 59 children (5-12yrs) with spastic diplegic CP (Gross Motor Function Classification System scores II - III) without fixed lower-limb contractures, illnesses impeding physiotherapy or history of recent botulinum toxin injection/surgery were recruited.
Children were randomized to Intervention or Control arms. Their 6-minute-walk Test (6MWT) scoring and clinical examination were performed at baseline, 3 and 6 months. Children in Intervention Arm (n=30) were prescribed parent-supervised home-centered activity-based therapy (walking, standing, squatting, climbing up/downstairs, kicking a ball, dancing, riding a tricycle/bicycle) in addition to their institutional physiotherapy. Children in Control Arm (n=29) were prescribed ongoing institutional physiotherapy alone. Logbooks, home videos and telephonic follow-ups were used to ensure compliance.
Comparison of the mean change in 6MWT scores at 6 months (from baseline) between the two groups.
Median (IQR) change in 6MWT scores at 6 months (from baseline) in the Intervention and Control arms were 3.5 (-5.3, 9) m and 3 (-7.8, 6.3) m.
Adjunct home-centered activity-based therapy was safe and feasible, but did not result in appreciable gains over 6 months.
Adjunct home-centered activity-based therapy was safe and feasible, but did not result in appreciable gains over 6 months.Histone acetylation which regulates about 2-10% of genes has been demonstrated to be involved in tumorigenesis of esophageal squamous cell carcinoma (ESCC). In this study, we investigated the treatment response of ESCC to selective histone deacetylase inhibitor (HDACi) LMK-235 and potential biomarker predicting the treatment sensitivity. We identified tensin-3 (TNS3) which was highly over-expressed in ESCC as one of the down-regulated genes in response to LMK-235 treatment. TNS3 was found positively correlated with the tumor malignancy and poor prognosis in the patients. Silencing TNS3 significantly inhibited ESCC cell proliferation both in vitro and in vivo, sensitizing the treatment response to LMK-235. Our findings provide an insight into understanding the oncogenic role of TNS3 in ESCC and its clinical application for HDAC targeted therapy of ESCC.